Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will evaluate the effect of investigational drugs, pembrolizumab alone or pembrolizumab with lenvatinib, on the immune systems response to kidney cancer when given before and after surgery to remove kidney cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzona histologicznie diagnoza raka nerki
- •Rak nerki w zaawansowanym stopniu (stadium kliniczne cT2-cT4)
- •Świadoma zgoda pacjenta na udział w badaniu
- •Biopsja potwierdzająca raka nerki wykonana podczas badania przesiewowego
✗ Disqualifies
- •Ciąża lub karmienie piersią
- •Mężczyźni i kobiety w wieku rozrodczym nieużywający skutecznej antykoncepcji przez okres leczenia i 7-120 dni po jego zakończeniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Abramson Cancer Center at University of Pennsylvania
Philadelphia, United States
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.